This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceuticalcompanies. Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.
AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drugdevelopment.” The promise to partners is to “move quickly. Reduce cost.
Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceuticalcompanies.
The university then licenses the IP to an existing pharmaceuticalcompany or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceuticalcompanies.
The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drugdevelopment, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.
Products like Onpattro® highlight how nanoparticles can safely and effectively deliver RNA-based therapies, with the potential to revolutionize treatments for a range of diseases. Download Your Free Copy Today Dive deeper into these advancements and gain actionable insights to accelerate your drugdevelopment efforts.
But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). It wasn’t a silver bullet to the hard problem of drugdevelopment, but it wasn’t too far off either. There was scFormer in 2022, scGPT in 2023, and plenty of others.
Introduction Biomarkers are becoming increasingly essential in drugdevelopment and clinical practice, driving the need for more precise validation methods. Given this, what’s holding drugdevelopers back? Advanced techniques like MSD and LC-MS/MS offer unmatched precision and sensitivity at a fraction of the cost.
About the Janssen PharmaceuticalCompanies of. We’re the PharmaceuticalCompanies of. is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Forward-Looking Statement of the Janssen PharmaceuticalCompanies of. Learn more at Learn more at.
As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drugdevelopers. The drug didn’t cure the animals at such low doses, but their health did improve, hinting at the drug’s efficacy. The researchers were left with 40 drug candidates.
About the Janssen PharmaceuticalCompanies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. About Moderna Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Learn more at Learn more at www.jnj.com.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content